间充质干细胞在移植物抗宿主病治疗与预防中的临床应用
Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease.
作者信息
Lin Yi, Hogan William J
机构信息
Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
出版信息
Adv Hematol. 2011;2011:427863. doi: 10.1155/2011/427863. Epub 2011 Dec 10.
Abstract
Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal differentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis and endogenous tissue repair by in vitro and animal studies. Clinical trials have examined the utility of these cells in autoimmune and inflammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges of this treatment modality in this disease setting.
摘要
间充质干细胞（MSCs）是具有多能间充质分化潜能的异质性基质细胞群体。体外研究和动物研究发现，它们具有免疫抑制特性以及调节血管生成和内源性组织修复的能力。临床试验已对这些细胞在自身免疫性疾病和炎症性疾病中的效用进行了研究。特别是在异基因造血干细胞移植（HSCT）中，已经开展了多项研究来探索使用间充质干细胞治疗急性和慢性移植物抗宿主病（GVHD），以及与造血干细胞移植联合移植以促进造血干细胞植入并预防移植物抗宿主病。我们在此回顾这些研究结果，并讨论这种治疗方式在该疾病背景下所面临的一些挑战。
相似文献
1
Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease.
Adv Hematol. 2011;2011:427863. doi: 10.1155/2011/427863. Epub 2011 Dec 10.
2
The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
Stem Cell Res Ther. 2019 Jun 21;10(1):182. doi: 10.1186/s13287-019-1287-9.
3
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
Biol Blood Marrow Transplant. 2005 May;11(5):389-98. doi: 10.1016/j.bbmt.2005.02.001.
4
Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Cytotherapy. 2016 Feb;18(2):172-85. doi: 10.1016/j.jcyt.2015.11.010.
5
Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?
Int J Mol Sci. 2017 May 9;18(5):1022. doi: 10.3390/ijms18051022.
6
Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
Stem Cell Res Ther. 2020 Feb 18;11(1):64. doi: 10.1186/s13287-020-01592-z.
7
Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia.
Cell Transplant. 2013;22(8):1381-94. doi: 10.3727/096368912X657666. Epub 2012 Oct 4.
8
Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28.
9
Mesenchymal stromal cells and hematopoietic stem cell transplantation.
Immunol Lett. 2015 Dec;168(2):215-21. doi: 10.1016/j.imlet.2015.06.013. Epub 2015 Jun 25.
10
Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?
Front Immunol. 2020 Dec 11;11:609063. doi: 10.3389/fimmu.2020.609063. eCollection 2020.
引用本文的文献
1
Hybrid Micro-/Nanoprotein Platform Provides Endocrine-like and Extracellular Matrix-like Cell Delivery of Growth Factors.
ACS Appl Mater Interfaces. 2024 Jul 3;16(26):32930-32944. doi: 10.1021/acsami.4c01210. Epub 2024 Jun 18.
2
The protective mechanism of Klotho gene-modified bone marrow mesenchymal stem cells on acute kidney injury induced by rhabdomyolysis.
Regen Ther. 2021 Aug 13;18:255-267. doi: 10.1016/j.reth.2021.07.003. eCollection 2021 Dec.
3
Cellular human tissue-engineered skin substitutes investigated for deep and difficult to heal injuries.
NPJ Regen Med. 2021 Jun 17;6(1):35. doi: 10.1038/s41536-021-00144-0.
4
Xeno-Free Human Wharton's Jelly Mesenchymal Stromal Cells Maintain Their Characteristic Properties after Long-Term Cryopreservation.
Cell J. 2021 Jul;23(2):145-153. doi: 10.22074/cellj.2021.7131. Epub 2021 May 26.
5
Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases.
Front Cell Dev Biol. 2021 Mar 9;9:643125. doi: 10.3389/fcell.2021.643125. eCollection 2021.
6
Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications.
Int J Mol Sci. 2020 Jul 28;21(15):5366. doi: 10.3390/ijms21155366.
7
Human umbilical cord-derived mesenchymal stem cells alleviate schizophrenia-relevant behaviors in amphetamine-sensitized mice by inhibiting neuroinflammation.
Transl Psychiatry. 2020 Apr 27;10(1):123. doi: 10.1038/s41398-020-0802-1.
8
PTPN21 Overexpression Promotes Osteogenic and Adipogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells but Inhibits the Immunosuppressive Function.
Stem Cells Int. 2019 Nov 21;2019:4686132. doi: 10.1155/2019/4686132. eCollection 2019.
9
Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells.
Leukemia. 2020 May;34(5):1383-1393. doi: 10.1038/s41375-019-0640-4. Epub 2019 Dec 3.
10
Canine Adipose-Derived Mesenchymal Stromal Cells Enhance Neuroregeneration in a Rat Model of Sciatic Nerve Crush Injury.
Cell Transplant. 2019 Jan;28(1):47-54. doi: 10.1177/0963689718809045. Epub 2018 Oct 28.
本文引用的文献
1
Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems.
Stem Cells. 2011 Jun;29(6):920-7. doi: 10.1002/stem.645.
2
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.
Haematologica. 2011 Jul;96(7):1072-6. doi: 10.3324/haematol.2010.038356. Epub 2011 Mar 10.
3
Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
Biol Blood Marrow Transplant. 2011 Apr;17(4):534-41. doi: 10.1016/j.bbmt.2010.04.014. Epub 2010 May 8.
4
Mesenchymal stem cells as therapeutics.
Annu Rev Biomed Eng. 2010 Aug 15;12:87-117. doi: 10.1146/annurev-bioeng-070909-105309.
5
Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28.
6
Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study.
Cytotherapy. 2010 Apr;12(2):265-8. doi: 10.3109/14653240903390795.
7
Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report.
Biol Blood Marrow Transplant. 2010 Mar;16(3):403-12. doi: 10.1016/j.bbmt.2009.11.006. Epub 2009 Nov 17.
8
Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells.
Transplant Proc. 2009 Oct;41(8):3347-52. doi: 10.1016/j.transproceed.2009.08.030.
9
Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases.
Int J Lab Hematol. 2010 Apr;32(2):256-64. doi: 10.1111/j.1751-553X.2009.01181.x. Epub 2009 Jul 28.
10
Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance.
Am J Transplant. 2009 Aug;9(8):1760-72. doi: 10.1111/j.1600-6143.2009.02721.x. Epub 2009 Jun 26.
Zotero 插件